These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16288878)

  • 61. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 62. Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.
    Weber B; Schlicker E; Sokoloff P; Stark H
    Br J Pharmacol; 2001 Aug; 133(8):1243-8. PubMed ID: 11498509
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown AM; Stemp G; Middlemiss DN
    Br J Pharmacol; 1999 Jul; 127(5):1135-44. PubMed ID: 10455259
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells.
    Robinson SW; Caron MG
    J Neurochem; 1996 Jul; 67(1):212-9. PubMed ID: 8666994
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms.
    Schetz JA; Chu A; Sibley DR
    J Pharmacol Exp Ther; 1999 May; 289(2):956-64. PubMed ID: 10215675
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 69. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Paradoxical regulation of dopamine receptors in transfected 293 cells.
    Filtz TM; Artymyshyn RP; Guan W; Molinoff PB
    Mol Pharmacol; 1993 Aug; 44(2):371-9. PubMed ID: 8102783
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potent haloperidol derivatives covalently binding to the dopamine D2 receptor.
    Schwalbe T; Kaindl J; Hübner H; Gmeiner P
    Bioorg Med Chem; 2017 Oct; 25(19):5084-5094. PubMed ID: 28666858
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites.
    Ronsisvalle G; Marrazzo A; Prezzavento O; Pasquinucci L; Falcucci B; Di Toro RD; Spampinato S
    Bioorg Med Chem; 2000 Jun; 8(6):1503-13. PubMed ID: 10896126
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulation of responsiveness at D2 dopamine receptors by receptor desensitization and adenylyl cyclase sensitization.
    Bates MD; Senogles SE; Bunzow JR; Liggett SB; Civelli O; Caron MG
    Mol Pharmacol; 1991 Jan; 39(1):55-63. PubMed ID: 1846220
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
    Sóvágó J; Makkai B; Gulyás B; Hall H
    Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
    [TBL] [Abstract][Full Text] [Related]  

  • 76. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.
    Yuan J; Chen X; Brodbeck R; Primus R; Braun J; Wasley JW; Thurkauf A
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2715-8. PubMed ID: 9873609
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuroprotective effects of high affinity Σ1 receptor selective compounds.
    Luedtke RR; Perez E; Yang SH; Liu R; Vangveravong S; Tu Z; Mach RH; Simpkins JW
    Brain Res; 2012 Mar; 1441():17-26. PubMed ID: 22285434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Derivatives of (R)-2-amino-5-methoxytetralin: antagonists and inverse agonists at the dopamine D2A receptor.
    Höök BB; Brege C; Linnanen T; Mikaels A; Malmberg A; Johansson AM
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2167-72. PubMed ID: 10465538
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
    Tu Z; Li S; Cui J; Xu J; Taylor M; Ho D; Luedtke RR; Mach RH
    J Med Chem; 2011 Mar; 54(6):1555-64. PubMed ID: 21348515
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets.
    Osinski MA; Uchic ME; Seifert T; Shaughnessy TK; Miller LN; Nakane M; Cox BF; Brioni JD; Moreland RB
    Pharmacol Biochem Behav; 2005 May; 81(1):211-9. PubMed ID: 15894081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.